Ignite Creation Date:
2025-12-24 @ 10:53 PM
Ignite Modification Date:
2025-12-29 @ 7:42 AM
Study NCT ID:
NCT01131169
Status:
COMPLETED
Last Update Posted:
2021-12-02
First Post:
2010-05-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-05
Start Date Type:
ACTUAL
Primary Completion Date:
2020-05-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-05-15
Completion Date Type:
ACTUAL
First Submit Date:
2010-05-25
First Submit QC Date:
None
Study First Post Date:
2010-05-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-04-08
Results First Submit QC Date:
None
Results First Post Date:
2021-12-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-04
Last Update Post Date:
2021-12-02
Last Update Post Date Type:
ACTUAL